Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Vertex Pharma (VRTX) Tops Q4 EPS by 8c, Offers Guidance
January 26, 2022 4:04 PM ESTVertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $3.37, $0.08 better than the analyst estimate of $3.29. Revenue for the quarter came in at $2.07 billion versus the consensus estimate of $2 billion.
GUIDANCE:
Vertex Pharma sees FY2022 revenue of $8.4-8.6 billion, versus the consensus... More
